Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: Conversations from the Front Lines of Drug Development
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 43

September 12, 2024 00:39:18
Episode Cover

Episode 43: Isaac Stoner, Co-founder and CEO at Octagon Therapeutics

"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than...

Listen

Episode 23

September 14, 2022 00:37:26
Episode Cover

Episode 23: Dr. Arun Bhatt, Consultant for Clinical Research and Drug Development in India

What makes India a smart and viable setting for today’s clinical trials? Join us for the latest episode of Few & Far Between. Biorasi's ...

Listen

Episode 39

March 26, 2024 00:45:10
Episode Cover

Episode 39: Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center

"Technologies have changed enormously in terms of how we can basically procure, preserve, and then interrogate a tumor specimen...like effectively in real time, like...

Listen